Exercise Capacity in Chronic Fatigue Syndrome

Archives of Internal Medicine

Vol. 160 No. 21, November 27, 2000


Pascale De Becker, PhD; Johan Roeykens, PT; Masha Reynders, PT; Neil McGregor, MD, PhD;

 Kenny De Meirleir, MD, PhD

 

Background  Patients with chronic fatigue syndrome (CFS) suffer from various symptoms, including debilitating fatigue, muscle pain, and muscle weakness. Patients with CFS can experience marked functional impairment. In this study, we evaluated the exercise capacity in a large cohort of female patients with CFS.

Methods  Patients with CFS and matched sedentary control subjects performed a maximal test with graded increase on a bicycle ergometer. Gas exchange ratio was continuously measured. In a second stage, we examined only those persons who achieved a maximal effort as defined by 2 end points: a respiratory quotient of at least 1.0 and an age-predicted target heart rate of at least 85%. Data were assessed using univariate and multivariate statistical methods.

Results  The resting heart rate of the patient group was higher, but the maximal heart rate at exhaustion was lower, relative to the control subjects. The maximal workload and maximal oxygen uptake attained by the patients with CFS were almost half those achieved by the control subjects. Analyzing only those persons who performed a maximal exercise test, similar findings were observed.

Conclusions  When compared with healthy sedentary women, female patients with CFS show a significantly decreased exercise capacity. This could affect their physical abilities to a moderate or severe extent. Reaching the age-predicted target heart rate seemed to be a limiting factor of the patients with CFS in achieving maximal effort, which could be due to autonomic disturbances.

Arch Intern Med. 2000;160:3270-3277

 

 


A DIAGNOSIS of chronic fatigue syndrome (CFS), as defined in 19941 by the Centers for Disease Control and Prevention (CDC), Atlanta, Ga, requires unexplained fatigue for more than 6 months not due to continuing exertion, not resolved by rest, and accompanied by 4 or more of the following 8 symptoms: sore throat, tender lymph nodes, memory and concentration problems, joint pain, headache of a new type, unrefreshing sleep, and postexertional malaise lasting more than 24 hours.  Chronic fatigue syndrome is characterized as a new onset of fatigue, serious enough to reduce daily activities by more than 50% and in the absence of any other medically identifiable disorders.1, 2  Patients with CFS exhibit marked impairment and sometimes have greater degrees of functional disability than do patients with other diseases such as type 2 diabetes mellitus, congestive heart failure, hypertension, acute myocardial infarction, major depression, relapsing or remitting multiple sclerosis,3 and acute infectious mononucleosis.4

Various studies have evaluated the ability of patients with CFS to perform exercise, but conflicting results have been published.5-10  Some authors believe the aerobic capacity of patients with CFS lies within the low normal range,6, 8, 9 whereas others report a reduced aerobic capacity relative to normal subjects5, 10 and to patients with irritable bowel syndrome.7  Taking into account that the population with CFS is very heterogeneous, these different findings could be due to a selection bias, the low number of individuals studied, or both.

The aerobic potential of an individual is determined by cardiac output and muscle oxidative capacity.  Muscle contractility also plays a very important role.11  Previous studies have considered whether these factors limit the ability to complete physically active tasks in CFS.9, 12-17  Although patients report significant reductions in physical capabilities and postexertional symptom exacerbation,12, 17 findings from their tests of muscle strength, endurance, and function are normal.9, 12, 17-21  Histological and metabolic studies give mixed results.  Several studies of patients with CFS have shown reductions in muscle oxidative capacity and metabolism,16, 22 atrophy of the fast twitch fibers,23-25 mitochondrial abnormalities,23, 24, 26 increased lactic acid production during exercise,13-15 and myopathic features on single fiber electromyogram.27

However, these abnormalities are not consistent, contributing to the consensus that CFS is a heterogeneous disorder and that differences in patient populations and muscles studied may account for discrepancies between studies.28  Some authors believe that central rather than peripheral factors are responsible for the reduced physical capacity and the difficulty in performing a maximal effort.9, 11, 17, 29  Patients with CFS have exhibited repetitively negative changing T waves at Holter registrations30 and a slow acceleration of heart rate during exercise.10 It is suggested that the fatigue in CFS may be related to subtle cardiac dysfunction occurring at workloads common to ordinary living.30

The pathophysiology of exercise has been studied extensively in relation to cardiovascular, pulmonary, endocrine, and neuromuscular diseases, but little information exists on the interrelationship between physical exercise parameters and CFS.31  As there is only scant information on the physical capacity of patients with CFS, physicians who are called on to assist in the determination of the physiological capacity of these patients have no standards to rely on.  The few studies that have been done involve limited numbers of patients, which could bias the results considering the heterogeneity of the CFS population.  Therefore, we judged it necessary to study a large group of patients to be able to draw conclusions on their exercise capacity and degree of impairment.

The standard for measuring exercise capacity has always been the maximal oxygen uptake (VO2max) during high intensity whole body exercise.11, 32  It is generally accepted that cardiopulmonary exercise testing is a good research tool for this purpose33 and is commonly used to determine an individual's exercise potential.34

We designed a maximal bicycle ergometric test against a graded increase in workload, which aimed to collect data regarding exercise capacity in a large cohort of female patients with CFS.  These results were compared with a population of sedentary control female subjects and with findings reported in the literature on other sedentary healthy populations.

METHODS

PATIENTS AND CONTROL SUBJECTS
A total of 450 consecutive female patients who met the CDC's 1988 or 1994 criteria for CFS were enrolled in the study, which had been approved by an ethical committee.  Of these, 427 met the requirements and agreed to participate.  The diagnosis of CFS was made by patient history, routine physical examination, and laboratory test results to exclude other relevant diagnoses, as recommended by Fukuda et al.1

A group of 204 age-matched sedentary women served as a control population.  We selected them from subjects who came for medical checkups.  Only those who did sitting work and performed a maximum of 1 hour of sports per week were included.  Control subjects were accepted into the study only if they denied having symptoms of chronic fatigue and did not suffer from any medical conditions known to cause chronic fatigue.

STUDY DESIGN
All patients and controls underwent a bicycle ergometric test against a graded increase in workload until exhaustion.  The exercise tests were performed at room temperature (20°C-22°C) and at a humidity of 40% to 60%.  The subjects assumed the sitting position on the electromagnetically braked ergometer (Jaeger 900; Lode B.V., Groningen, the Netherlands), and the test was started after 3 to 5 minutes of adjustment.  Heart rate was continuously monitored at rest and during exercise . There was continuous recording of the 12-lead electrocardiogram using an electrocardiograph (Marquette Electronics Inc, Milwaukee, Wis).  An open circuit spirometer (Mijnhart Oxycon; IBM, Bunnik, the Netherlands) with automatic printout every 30 seconds was used to collect pulmonary data during the test.  As such, data for VO2max and maximal carbon dioxide production were averaged for every 30-second interval during each stage. Expired air was collected via a 2-way breathing valve attached to a mask that covered the subject's nose and mouth and was analyzed continuously for ventilatory and metabolic variables.  Before each test, the spirometer was calibrated for ambient conditions.

The increments were chosen to obtain a total exercise duration between 8 and 12 minutes, which is suggested as an optimal test period.34  Thus, the duration of exercise was kept below 15 minutes to avoid possible early onset fatigue in the lower limbs because of lack of physical fitness.  The patients with CFS started at 10 W, with an increase of 10 W/min.  The control population began at 40 W, with an increase of 30 W every 3 minutes.

The following parameters were measured: heart rate at rest (HRrest), maximal heart rate (HRmax), maximal work capacity attained, VO2max per kilogram of body weight, maximal respiratory quotient (RQmax), heart rate at RQ of 1.0 (HRAT), peak work rate at RQ of 1.0 (WAT), and the percentage of target heart rate (THR) that was achieved.  The metabolic data analyzed were the means of the last 30 seconds from the final stage of exercise or the highest value attained if a decline in VO2 occurred at the final workload.

A separate analysis between patients and controls was done with all those who performed a maximal exercise test.  The criteria used for determining whether the subject had attained a physiological maximum were the accomplishment of 2 end points: (1) an RQ greater than 1.0 and (2) reaching at least 85% of the age-predicted THR.  The HRmax achievable during exercise of large muscles (eg, with use of a bicycle ergometer) is generally equivalent to 220 minus the subject's age in years, plus or minus 20 beats per minute.35

Data were sent to Neil McGregor, MD, PhD, at the University of Newcastle, Australia, for independent analysis to reduce any possibility of bias.

STATISTICAL ANALYSIS
Data distributions were evaluated for violations of assumptions with parametric statistical analyses.  The percentage of THR was arcsine transformed, while all other exercise response variables were log transformed to improve normality and linearity.  Subject characteristics were assessed using x2 probability and
t tests. Univariate group differences were evaluated on untransformed data using the nonparametric Mann-Whitney test.  Multivariate group differences were determined on transformed data using standard and forward stepwise discriminant function analyses.  Pearson product moment correlation was used to investigate within-group differences in the associations between variables.  These data were processed using statistical software (Access97 and Excel97; Microsoft, Redmond, Wash, and Statistica, version 5.1; Statsoft, Tulsa, Okla).

RESULTS

There was no difference in age between the patients with CFS and the control subjects (mean + SD years, 37.0 + 9.0 and 35.9 + 9.2, respectively).  All individuals in the study were white Europeans.  Those with CFS had a mean illness duration of 7.0 + 6.4 years.

Discriminant function analysis was applied to determine the major characteristics that differentiated between the exercise response profiles of the CFS vs the control subjects.  Table 1 shows that the regression model revealed a large deviation in the response characteristics between them (Wilks λ= 0.14, F = 199.4; P<.001), with a high degree of homogeneity within the 2 groups.  Most (97.8%) of the control subjects complied with the control model profile, and 99.7% of individuals with CFS complied with the CFS group profile.  Univariate analysis showed that 10 of the 15 exercise profile measures were reduced in those with CFS compared with the control subjects and 1 parameter (HRrest) was increased.

Forward stepwise discriminant function analysis was used to assess the major parameters that determined the different response characteristic profiles in the CFS vs the control groups.  A strong model was found (Wilks λ = 0.136, F = 301.3), with HRAT being the primary discriminating variable, followed by WAT and the maximal workload per kilogram of body weight (P<.001 for all).  Thus, the exercise response characteristics of the CFS and the control subjects were very dissimilar, principally in HRAT and WAT.

Pearson product moment correlation analysis was undertaken to assess any differences in the exercise parameters between the 2 groups to allow a better understanding of how exercise capacity varied.  Table 2 summarizes the correlation comparisons between WAT and HRAT with the heart rate parameters and RQ in the patients with CFS vs the control subjects.  There was a significant disregulation of the relationships between WAT and HRAT with disregulation of the heart rate parameters.  Therefore, variation in heart rate was strongly related to changes in exercise capacity in the patients with CFS.

Figure 1 shows the comparative scatterplot of WATand HRAT in the 2 groups.  While there was a similar correlation between WAT and HRAT (CFS, r = 0.50; control, r = 0.56; P<.001 for both), there was a large reduction in both parameters in the patients with CFS (Table 1).  Figure 2, Figure 3, and Figure 4 illustrate the association between HRAT and WAT, VO2max, and exercise duration in the patients with CFS and in control subjects.  These figures demonstrate that the relationships between these 3 factors were quite different in the 2 groups.

The maximal respiratory quotient was positively correlated with exercise duration, HRmax, and the percentage of THR in both groups (all r >0.25; P<.001).  In the patients with CFS, RQmax was positively associated with WAT(r = 0.26; P<.001) and negatively associated with HRAT (r = -0.15; P<.01).  In the control individuals, RQmax was positively correlated with HRrest (r = 0.17; P<.02) and negatively correlated with WAT(r = -0.24; P<.002).

The percentage of THR was positively associated with exercise duration, HRrest and HRmax, maximum workload, VO2max, HRAT and WAT, and RQmax in both groups (all r >0.25; P<.001).  In the control subjects, the percentage of THR was negatively correlated with the THR (r = -0.16; P<.04).  In those with CFS, the percentage of THR had a statistically higher correlation coefficient for WAT (CFS = 0.63, control = 0.15; P<.001, for difference) and maximum workload (CFS = 0.53, control = 0.28; P<.002, for difference) and a statistically lower correlation coefficient for HRAT (CFS = 0.31, control = 0.52; P<.007, for difference).  Thus, in patients with CFS, the reduction in the percentage of THR achieved was associated with a reduction in workload capacity.

Those with CFS had a higher HRrest and a lower HRmax relative to the control subjects (Table 1), and therefore the increase from resting to maximum heart rate was calculated for the sake of comparison.  It was lower in the patients with CFS vs the control subjects (CFS = 62.5 + 19.0 beats per minute, control = 88.9 + 14.4 beats per minute; P<.001).  In the CFS group, the increase in heart rate from rest to maximum had a higher positive correlation with the maximum workload (CFS = 0.68; control = 0.45) and exercise duration (CFS = 0.68; control = 0.47) (P<.001 for all) compared with the control subjects.

In the second stage of the study, we examined only those persons who attained a maximal effort as defined by 2 end points: achievement of an RQ of at least 1.0 and an age-predicted THR of at least 85%.  A relatively small percentage of patients with CFS, 37%, reached both criteria (Table 3).  The target heart rate seemed to be the limiting factor, since only 41% of the patients achieved an HRmax of at least 85% of the age-predicted THR, whereas 80% of them reached the anaerobic threshold defined by a minimal RQ of 1.0.  Thus, for comparison, we analyzed the metabolic data of those subjects who had achieved a maximal effort in both study groups (Table 4).

There was no difference in age between the 141 patients with CFS and the 158 control subjects (mean + SD years, CFS = 36.2 + 9.4; control = 35.5 + 9.0) who achieved maximal effort.  Those with CFS had a mean illness duration of 6.8 + 7.0 years.

Discriminant function analysis was applied to determine the major differences between the exercise response characteristics of the patients with CFS vs the control subjects who achieved maximal effort.  Table 4 shows that the regression model revealed a large difference in these characteristics (Wilks λ= 0.10, F = 158.8; P<.001), with a high degree of homogeneity within the 2 groups.  All of the control subjects complied with the control model profile, and 99.3% of the patients with CFS complied with the CFS group profile.  Univariate analysis demonstrated that 8 of the 15 exercise profile measures were reduced in the CFS group relative to the control group and 2 were increased (HRrest and WAT).  Compared with the initial analysis in the entire study group, the patients with CFS who achieved maximal responses showed no difference in exercise duration.  Most of the exercise parameters found to be dissimilar between the CFS and control groups were the same in patients who achieved maximal responses relative to those in the entire cohort of patients with CFS.  Therefore, the exercise capacity in the patients with CFS who reached their maximal response was still quite different from that of the control subjects.

Forward stepwise discriminant function analysis was applied to evaluate the major parameters that determined the differences between the exercise response characteristic profiles of the CFS vs the control groups who achieved maximal effort.  A strong model was found (Wilks λ = 0.11, F = 184.3), with HRAT being the primary discriminating variable, followed by WAT and maximal workload per kilogram of body weight (P<.001 for all).  These data show that the parameters differentiating the 2 groups were the same when analyzing only those in the cohort who achieved maximal exercise responses.

COMMENT

Exercise capacity was evaluated in a large cohort of female patients with CFS and compared with that of sedentary control subjects.  The O2max levels of our control group were consistent with various studies in untrained women of approximately the same age describing VO2max levels of 30 to 36 mL/kg per minute).31, 32  Our patients with CFS had an average VO2max just below 20 mL/kg per minute, representing significant impairment relative to the controls.  Comparing the exercise capacity in our patients with data from other studies shows a functionality similar to that of elderly healthy controls (60-69 years),31 individuals with chronic heart failure,36 patients with chronic obstructive or restrictive pulmonary disease,37 and those with skeletal muscle disorder.38  The decrease in physical capacity in patients with CFS appears to be associated with disease severity and is consistent with the reduction seen in many other chronic illnesses.

A major criterion for defining CFS is that patients report a greater than 50% reduction in activity levels relative to their pre-illness state.2  Maximal workload at exhaustion averaged 53% of normal in our patients with CFS, which is close to the 50% decrease in physical capabilities described in the CDC's criteria for CFS.1, 2

Sisto6 and Riley7 and their colleagues reported only slight reductions in aerobic power on a graded treadmill test in female patients with CFS.  Their patients had an average VO2max of 30.1 mL/kg per minute and 31.7 mL/kg per minute, respectively, which places them within the range of sedentary control subjects according to the classification by MacAuley et al.32  We believe that the failure to assess the more severely affected patients appears to have led to a disparity in study conclusions about the exercise capacity in patients with CFS.

In contrast to many investigators5-8 who have claimed heterogeneity of laboratory and exercise findings when comparing their results with other CFS studies, our study shows a high degree of homogeneity within the CFS group in multivariate analysis.  Our statistical homogeneity is an assessment of the differences between the 2 groups evaluated and does not necessarily reflect clinical homogeneity.  The contradictions between our study and the heterogeneous findings in other studies may also result from the array of measures used, different study designs and numbers, and various interpretations given to the results of those investigations.

Only a small number of patients with CFS reached both parameters for maximal exercise testing (RQ >1.0 and HRmax >85% THR).  However, when we analyzed the entire cohort data using only those subjects who fulfilled the criteria for maximal exercise, we still observed the same differences in exercise capacity between the CFS group and the control subjects.  Multiple regression analysis showed that the same parameters differentiated between the CFS and control groups as in the cohort.

The resting heart rate was higher in patients with CFS, as in other studies.5, 7  Moreover, most of our patients were not able to achieve their age-predicted THR, a finding that is in agreement with some previous studies in CFS.8, 10, 17, 20  Although some authors5, 8 believe that the inability to reach the THR indicates incapability to exercise to full capacity, because of elevated perceptions of exertion or fatigue or physical deconditioning, a large percentage of our patients who did not reach their age-predicted THR did reach their RQ of 1.0.  Furthermore, Gibson et al17 observed similar heart rates at increasing workloads in CFS and control subjects, which is more consistent with submaximal exertion than with deconditioning.5  The increase in HRrest associated with a lower achieved HRmax suggests that alteration in cardiac function is a primary factor associated with the reduction in exercise capacity in CFS.

It is a peculiar finding that, although most of our patients reached the respiratory anaerobic threshold, far fewer of them also reached their THR.  This would also indicate that suboptimal cardiac function is a major limiting factor in exercise capacity in patients with CFS.  Fischler et al5 use only the THR criteria to assess whether a patient did or did not perform a maximal effort.  This would suggest that too great an emphasis is placed on the THR, especially since several studies39-43 suggest autonomic nervous system involvement in CFS that could influence the chronotropic cardiac systems.  It could be that the increased HRrest and the low HRmax are the result of a disturbed autonomic system.  Possible disturbances include sympathetic predominance,37, 42 diminished vagal power,41 and reduced sympathetic responsiveness to stress42 and exercise.44  Considering that 66% to 90% of patients with CFS initially develop an acute infectious illness,45 exercise bradycardia might also be related to post-acute viral status, either as a direct or indirect latent effect, and the possibility that cellular metabolic pathways are disrupted by the viral presence or by some immunological process triggered by the acute or persistent infection.46

The exact mechanisms for this are speculative.  It may be that loss of muscle protein contributes to the perceived muscle weakness.47  Cytokine abnormalities and dysfunction of the 2-5A Synthetase/RNaseL pathway exert a negative control on protein synthesis.  Both of these anomalies have been demonstrated in CFS.48-50  In addition, muscle fiber atrophy23-25 and a defect in muscle energy sources need to be explored as there is disagreement whether patients with CFS show defects in mitochondrial function.14, 23, 24, 26

This study clearly shows that patients with CFS are limited in their physical capacities.  Based on the American Medical Association Guidelines for Impairment Rating,51 our 55.2% of patients who had a VO2max of less than 20 mL/kg per minute correspond to class 3-4 on the disability scale, indicating moderate to severe impairment.51  Regardless of the cause and pathogenesis, the symptom complex labeled CFS can and does result in prolonged debilitation.3, 4, 51

To our knowledge, this is the first study on exercise capacity in a large population of patients with CFS and sedentary control subjects.  Physical capacity based on exercise tolerance is only one of a number of factors that might be considered in establishing a more global impairment rating.  However, we believe it is a strong and useful tool in assessing a person's physical capability.


 
Author/Article Information

From the Human Performance Laboratory and Department of Internal Medicine, Faculty of Physical Education and Physical Therapy, Vrije Universiteit Brussel, Brussels, Belgium (Drs De Becker and De Meirleir, Mr Roeykens, and Ms Reynders); and the Collaborative Pain Research Unit, Department of Biological Sciences, Faculty of Science, University of Newcastle, Callaghan, New South Wales, Australia (Dr McGregor).
 
Corresponding author: Pascale De Becker, PhD, Human Performance Laboratory and Department of Internal Medicine, Faculty of Physical Education and Physical Therapy, Vrije Universiteit Brussel, LK–Third Floor, Pleinlaan 2, 1050 Brussels, Belgium (e-mail
: pdbeck@minf.vub.ac.be).

Accepted for publication June 7, 2000.

 

REFERENCES


1.  Fukuda K, Straus SE, Hickie I, et al.  The chronic fatigue syndrome: a comprehensive approach to its definition and study. Ann Intern Med.1994;121:953-959.
2.   Holmes GP, KaplanJE, Gantz NM, et al.  Chronic fatigue syndrome: a working case definition. Ann Intern Med. 1988; 108:387-389.
3.   Komaroff AL, Fagioli LR, Doolittle TH, et al.  Health status in patients with chronic fatigue syndrome and in general population and disease comparison groups.   Am J Med. 1996;101:281-290.

4.   Buchwald D, Pearlman T, Umali J, Schmaling K, Katon W.  Functional status in patients with chronic fatigue syndrome, other fatiguing illnesses, and healthy individuals.  Am J Med. 1996;101:364-370.

5.   Fischler B, Dendale P, Michiels V, Cluydts R, Kaufmann L, De Meirleir K.   Physical fatigability and exercise capacity in the chronic fatigue syndrome: association with disability, somatisation, and psychopathology.  J Psychosom Res. 1997;42:369-378.

6.   Sisto SA, Lamanca J, Cordero DL, et al.  Metabolic and cardiovascular effects of a progressive exercise test in patients with chronic fatigue syndrome.  Am J Med. 1996; 100:634-640.

7.   Riley MS, O'Brien CJ, McCluskey DR, Bell NP, Nicholls DP.  Aerobic work capacity in patients with chronic fatigue syndrome.  BMJ. 1990;301:953-956.

8.   Rowbottom D, Keast D, Pervan Z, Morton A.  The physiological response to exercise in chronic fatigue syndrome.  J Chronic Fatigue Syndrome. 1998;4:33-49.

9.   Kent-Braun JA, Sarma KR, Weiner MW, Massie B, Miller RG.  Central basis of muscle fatigue in chronic fatigue syndrome.
Neurology. 1993;43:125-131.

10.   Montague TJ, Marrie TJ, Klassen GA, Bewick DJ, Horacek BM.  Cardiac function at rest and with exercise in the chronic fatigue syndrome.  Chest. 1989;95:779-784.

11.   Noakes TD.  Implications of exercise testing for prediction of athletic performance: a contemporary perspective.  Med Sci Sports Exerc. 1988;20:319-330.

12.   McCully KK, Sisto SA, Natelson BH.  Use of exercise for treatment of chronic fatigue syndrome.  Sports Med. 1996;21:35-48.

13.   Arnold DL, Bore PJ, Radda GK, Styles P, Taylor DJ.  Excessive intracellular acidosis of skeletal muscle on exercise in a patient with a post-viral exhaustion/fatigue syndrome.  Lancet. 1984;1:1367-1369.

14.   Barnes PR, Taylor DJ, Kemp GJ, Radda GK.  Skeletal muscle bioenergetics in the chronic fatigue syndrome.  J Neurol Neurosurg Psychiatry. 1993;56:679-683.

15.   Lane RJ, Barrett MC, Woodrow D, Moss J, Fletcher R, Archard LC.  Muscle fibre characteristics and lactate responses to exercise in chronic fatigue syndrome.  J Neurol Neurosurg Psychiatry. 1998;64:362-367.

16.   Wong R, Lopaschuk G, Zhu G, et al.  Skeletal muscle metabolism in the chronic fatigue syndrome: in vivo assessment by 31P nuclear magnetic resonance spectroscopy.  Chest. 1992;102:1716-1722.

17.   Gibson H, Carroll N, Clague JE, Edwards RH.  Exercise performance and fatiguability in patients with chronic fatigue syndrome.  J Neurol Neurosurg Psychiatry. 1993;56:993-998.

18.   Lloyd AR, Gandevia SC, Hales JP.  Muscle performance, voluntary activation, twitch properties and perceived effort in normal subjects and patients with the chronic fatigue syndrome.  Brain. 1991;114:85-98.

19.   Lloyd AR, Hales JP, Gandevia SC.  Muscle strength, endurance and recovery in the post-infection fatigue syndrome.  J Neurol Neurosurg Psychiatry. 1988;51:1316-1322.

20.   Stokes MJ, Cooper RG, Edwards RH.  Normal muscle strength and fatigability in patients with effort syndromes.  BMJ. 1988;297:1014-1017.

21.   Rutherford OM, White PD.  Human quadriceps strength and fatiguability in patients with post viral fatigue.  J Neurol Neurosurg Psychiatry. 1991;54:961-964.

22.   McCully KK, Natelson BH, Iotto S, Sisto S, Leigh JS.  Reduced oxidative muscle metabolism in chronic fatigue syndrome.
Muscle Nerve. 1996;19:621-625.

23.   Behan WM, More IA, Behan PO.  Mitochondrial abnormalities in the postviral fatigue syndrome.  Acta Neuropathol (Berl). 1991;83:61-65.

24.   Byrne E, Trounce I.  Chronic fatigue and myalgia syndrome: mitochondrial and glycolytic studies in skeletal muscle.  J Neurol Neurosurg Psychiatry. 1987;50:743-746.

25.   Gow JW, Behan WM, Simpson K, et al.  Studies on enterovirus in patients with chronic fatigue syndrome.  Clin Infect Dis. 1994;18(suppl 1):S126-S129.

26.   Behan WMH, Holt IJ, Kay DH, Moonie P.  In vitro study of muscle aerobic metabolism in chronic fatigue syndrome.  J Chronic Fatigue Syndrome. 1999;5:3-15.

27.   Jamal GA, Hansen S.   Post-viral fatigue syndrome: evidence for underlying organic disturbance in the muscle fibre. Eur Neurol. 1989;29:273-276.

28.   Lodi R, Taylor DJ, Radda GK.  Chronic fatigue syndrome and skeletal muscle mitochondrial function.  Muscle Nerve. 1997;20:765-766.

29.   Edwards RH, Gibson H, Clague JE, Helliwell T.   Muscle physiology and histopathology in chronic fatigue syndrome.
In: Bock GR, Whelan J, eds. Chronic Fatigue Syndrome. Chichester, England: John Wiley & Sons Ltd; 1993:102-131.

30.   Lerner AM, Lawrie C, Dworkin HS.  Repetitively negative changing T waves at 24-h electrocardiographic monitors in patients with the chronic fatigue syndrome.  Chest. 1993;104:1417-1421.

31.   Lewis SF, Haller RG.   Physiologic measurement of exercise and fatigue with special reference to chronic fatigue syndrome.  Rev Infect Dis. 1991;13(suppl 1):S98-S108.

32.   MacAuley D, McCrum EE, Stott G, et al.  Levels of physical activity, physical fitness and their relationship in the Northern Ireland Health and Activity Survey.  Int J Sports Med. 1998;19:503-511.

33.   Hollmann W, Prinz JP.  Ergospirometry and its history.  Sports Med. 1997;23:93-105.

34.   Davis JA.  Direct determination of aerobic power.  In: Maud PJ, Foster C, eds. Physiological Assessment of Human Fitness. Champaign, Ill: Human Kinetics; 1995:9-17.

35.   Astrand PO, Rodahl K.  Evaluation of physical performance on the basis of tests.  In: Astrand PO, Rodahl K, eds. Textbook of Work Physiology: Physiological Bases of Exercise. 3rd ed. New York, NY: McGraw-Hill; 1986:354-387.

36.   Wilson JR, Martin JL, Schwartz D, Ferraro N.   Exercise intolerance in patients with chronic heart failure: role of impaired nutritive flow to skeletal muscle.  Circulation. 1984;69:1079-1087.

37.   Wehr KL, Johnson RL Jr.   Maximal oxygen consumption in patients with lung disease.  J Clin Invest. 1976;58:880-890.

38.   Lewis SF, Haller RG.   Skeletal muscle disorders and associated factors that limit exercise performance.  Exerc Sport Sci Rev. 1989;17:67-113.

39.   Bou-Holaigah I, Rowe PC, Kan J, Calkins H.   The relationship between neurally mediated hypotension and the chronic fatigue syndrome.  JAMA. 1995;274:961-967.

40.   De Becker P, Dendale P, De Meirleir K, Campine I, Vandenborne K, Hagers Y.   Autonomic testing in patients with chronic fatigue syndrome.  Am J Med. 1998;105(3A):22S-26S.

41.   Sisto SA, Tapp W, Drastal S, et al.   Vagal tone is reduced during paced breathing in patients with the chronic fatigue syndrome.  Clin Auton Res. 1995;5:139-143.

42.   Pagani M, Lucini D, Mela GS, Langewitz W, Malliani A.   Sympathetic overactivity in subjects complaining of unexplained fatigue.  Clin Sci (Colch). 1994;87:655-661.

43.   Freeman R, Komaroff AL.   Does the chronic fatigue syndrome involve the autonomic nervous system?  Am J Med. 1997;102:357-364.

44.   Cordero DL, Sisto SA, Tapp WN, et al.   Decreased vagal power during treadmill walking in patients with chronic fatigue syndrome.  Clin Auton Res. 1996;6:329-333.

45.   Schluederberg A, Straus SE, Peterson P, et al.   Chronic fatigue syndrome research: definition and medical outcome assessment.  Ann Intern Med. 1992;117:325-331.

46.   Montague T, Marrie T, Klassen G, et al.   Cardiac effects of common viral illnesses.  Chest. 1988;94:919-925.

47.   Preedy VR, Smith DG, Salisbury JR, Peters TJ.   Biochemical and muscle studies in patients with acute post-viral fatigue syndrome.  J Clin Pathol. 1993;46:722-726.

48.   Lloyd A, Hickie I, Brockman A, Dwyer J, Wakefield D.   Cytokine levels in serum and cerebrospinal fluid in patients with chronic fatigue syndrome and control subjects.  J Infect Dis. 1991;164:1023-1024.

49.   Suhadolnik RJ, Reichenbach NL, Hitzges P, et al.  Upregulation of the 2-5A Synthetase/RNaseL antiviral pathway associated with chronic fatigue syndrome.  Clin Infect Dis. 1994;18(suppl 1):S96-S104.

50.   Suhadolnik RJ, Peterson DL, O'Brien K, et al.   Biochemical evidence for a novel low molecular weight RNaseL in chronic fatigue syndrome.  J Interferon Cytokine Res. 1997;17:377-385.

51.   Make B, Jones JF.   Impairment of patients with chronic fatigue syndrome.  J Chronic Fatigue Syndrome. 1997;3:43-55.


 

© 2000 American Medical Association

 

 

 

 

 

 

 

Mitochondrial abnormalities in the postviral fatigue syndrome.
Behan WM, More IA, Behan PO
Department of Pathology, University of Glasgow, Scotland.
Acta Neuropathol 1991;83(1):61-5

We have examined the muscle biopsies of 50 patients who had postviral fatigue syndrome (PFS) for from 1 to 17 years. We found mild to severe atrophy of type II fibres in 39 biopsies, with a mild to moderate excess of lipid. On ultrastructural examination, 35 of these specimens showed branching and fusion of mitochondrial cristae. Mitochondrial degeneration was obvious in 40 of the biopsies with swelling, vacuolation, myelin figures and secondary lysosomes. These abnormalities were in obvious contrast to control biopsies, where even mild changes were rarely detected. The findings described here provide the first evidence that PFS may be due to a mitochondrial disorder precipitated by a virus infection. 

PMID: 1792865, UI: 92170301

 

Central basis of muscle fatigue in chronic fatigue syndrome.
Kent-Braun JA, Sharma KR, Weiner MW, Massie B, Miller RG
Department of Neurology, University of California, San Francisco.
Neurology 1993 Jan;43(1):125-31

We studied whether muscle fatigue, metabolism, or activation are abnormal in the chronic fatigue syndrome (CFS). Subjects performed both an intermittent submaximal and a sustained maximal voluntary isometric exercise protocol of the tibialis anterior muscle. The extent of fatigue, metabolic response, and changes in both M-wave amplitude and twitch tension during exercise were similar in patients and controls. The response to systemic exercise was also normal in the patients. However, voluntary activation of the tibialis was significantly lower in the patients during maximal sustained exercise. The results indicate that patients with CFS have (1) normal fatigability and metabolism at both the intracellular and systemic levels, (2) normal muscle membrane function and excitation-contraction coupling, and (3) an inability to fully activate skeletal muscle during intense, sustained exercise. This failure of activation was well in excess of that found in controls, suggesting an important central component of muscle fatigue in CFS. 

PMID: 8423875, UI: 93140980

 

Impaired oxygen delivery to muscle in chronic fatigue syndrome.
McCully KK, Natelson BH
Department of Medicine, Medical College of Pennsylvania and Hahnemann University, Philadelphia, PA 19129, USA. kmccully@coe.uga.edu
Clin Sci (Colch) 1999 Nov;97(5):603-8

The purpose of this study was to determine if chronic fatigue syndrome (CFS) is associated with reduced oxygen delivery to muscles.  Patients with CFS according to CDC (Center for Disease Control) criteria (n=20) were compared with normal sedentary subjects (n=12).  Muscle oxygen delivery was measured as the rate of post-exercise and post-ischaemia oxygen-haem resaturation.  Oxygen-haem resaturation was measured in the medial gastrocnemius muscle using continuous-wavelength near-IR spectroscopy.  Phosphocreatine resynthesis was measured simultaneously using (31)P magnetic resonance spectroscopy.  The time constant of oxygen delivery was significantly reduced in CFS patients after exercise (46.5+/-16 s; mean+/-S.D.) compared with that in controls (29.4+/-6.9 s).  The time constant of oxygen delivery was also reduced (20.0+/-12 s) compared with controls (12.0+/-2.8 s) after cuff ischaemia.  Oxidative metabolism was also reduced by 20% in CFS patients, and a significant correlation was found between oxidative metabolism and recovery of oxygen delivery.  In conclusion, oxygen delivery was reduced in CFS patients compared with that in sedentary controls. This result is consistent with previous studies showing abnormal autonomic control of blood flow.  Reduced oxidative delivery in CFS patients could be specifically related to CFS, or could be a non-specific effect of reduced activity levels in these patients.  While these results suggest that reduced oxygen delivery could result in reduced oxidative metabolism and muscle fatigue, further studies will be needed to address this issue.

PMID: 10545311

 

 

Skeletal muscle metabolism in the chronic fatigue syndrome. In vivo assessment by 31P nuclear magnetic resonance spectroscopy.
Wong R, Lopaschuk G, Zhu G, Walker D, Catellier D, Burton D, Teo K, Collins-Nakai R, Montague T
Department of Medicine, University of Alberta, Edmonton, Canada.
Chest 1992 Dec;102(6):1716-22

BACKGROUND: Previous study of patients with chronic fatigue syndrome (CFS) has demonstrated a markedly reduced dynamic exercise capacity, not limited by cardiac performance and in the absence of clinical neuromuscular dysfunction, suggesting the possibility of a subclinical defect of skeletal muscle. METHODS: The in vivo metabolism of the gastrocnemius muscles of 22 CFS patients and 21 normal control subjects was compared during rest, graded dynamic exercise to exhaustion and recovery, using 31P nuclear magnetic resonance (NMR) spectroscopy to reflect minute-to-minute intracellular high-energy phosphate metabolism. RESULTS: Duration of exercise was markedly shorter in the CFS patients (8.1 +/- 2.8 min) compared with the normal subjects (11.3 +/- 4.3 min) (p = 0.005). There were large changes in phosphocreatine (PCr), inorganic phosphate (Pi), and pH from rest to clinical fatigue in all subjects, reflecting the high intensity of the exercise. The temporal metabolic patterns were qualitatively similar in the CFS patients and normal subjects. There were early and continuous changes in PCr and Pi that peaked at the point of fatigue and rapidly reversed after exercise. In contrast, pH was relatively static in early exercise, not declining noticeably until 50 percent of total exercise duration was achieved, and reaching a nadir at 2 min postexercise, before rapidly reversing. There were no differences in pH at rest (7.08 +/- 0.04 vs 7.10 +/- 0.04), exhaustion (6.85 +/- 0.17 vs 6.76 +/- 0.17) or early (6.64 +/- 0.25 vs 6.56 +/- 0.24) or late recovery (7.09 +/- 0.04 vs 7.10 +/- 0.05), CFS patients vs normal subjects, respectively (NS). Neither were there intergroup differences (NS) in PCr or Pi. Although, quantitatively, the changes in PCr, Pi, and pH were marked and similar in both groups from rest to exhaustion, the changes all occurred much more rapidly in the CFS patients. Moreover, adenosine triphosphate (ATP) was significantly (p = 0.007) less at exhaustion in the CFS group. CONCLUSIONS: Patients with CFS and normal control subjects have similar skeletal muscle metabolic patterns during dynamic exercise and reach similar clinical and metabolic end points. However, CFS patients reach exhaustion much more rapidly than normal subjects, at which point they also have relatively reduced intracellular concentrations of ATP. These data suggest a defect of oxidative metabolism with a resultant acceleration of glycolysis in the working skeletal muscles of CFS patients. This metabolic defect may contribute to the reduced physical endurance of CFS patients. Its etiology is unknown. Whether CFS patients' overwhelming tiredness at rest has a similar metabolic pathophysiology or etiology also remains unknown.

PMID: 1446478, UI: 93076532 

 

 

Specific oxidative alterations in vastus lateralis muscle of patients with the diagnosis of chronic fatigue syndrome

Stefania Fulle (a), Patrizia Mecocci (b), Giorgio Fano (c), Iacopo Vecchiet (d), Alba Vecchini (e), Delia Racciotti (d), Antonio Cherubini (b), Eligio Pizzigallo (d), Leonardo Vecchiet (c), Umberto Senin (b) and  M. Flint Beal (f). 

Address correspondence to: Dr. M. Flint Beal, Chairman, Neurology Department, New York Hospital-Cornell Medical Center,  525 East 68th Street,   New York, NY 10021, USA; Tel: (212) 746-6575; Fax: (212) 746-8532; email: fbeal@mail.med.cornell.edu

Free Radical Biology and Medicine  Dec 15, 2000, Vol. 29, No. 12,  1252-59

Chronic fatigue syndrome (CFS) is a poorly understood disease characterized by mental and physical fatigue, most often observed in young white females.  Muscle pain at rest, exacerbated by exercise, is a common symptom. Although a specific defect in muscle metabolism has not been clearly defined, yet several studies report altered oxidative metabolism.  In this study, we detected oxidative damage to DNA and lipids in muscle specimens of CFS patients as compared to age-matched controls, as well as increased activity of the antioxidant enzymes catalase, glutathione peroxidase, and transferase, and increases in total glutathione plasma levels.  From these results we hypothesize that in CFS there is oxidative stress in muscle, which results in an increase in antioxidant defenses.  Furthermore, in muscle membranes, fluidity and fatty acid composition are significantly different in specimens from CFS patients as compared to controls and to patients suffering from fibromyalgia.  These data support an organic origin of CFS, in which muscle suffers oxidative damage. 

 

 

Reduced oxidative muscle metabolism in chronic fatigue syndrome.
McCully KK, Natelson BH, Iotti S, Sisto S, Leigh JS Jr
Department of Medicine, Medical College of Pennsylvania, Philadelphia 19131, USA.
Muscle Nerve  1996  May;19(5):621-5

The purpose of this study was to determine if chronic fatigue syndrome (CSF) is characterized by abnormalities in oxidative muscle metabolism. Patients with CFS according to Centers for Disease Control (CDC) criteria (n = 22) were compared to normal sedentary subjects (n = 15). CFS patients were also tested before and 2 days after a maximal treadmill test. Muscle oxidative capacity was measured as the maximal rate of postexercise phosphocreatine (PCr) resynthesis using the ADP model (Vmax) in the calf muscles using 31P magnetic resonance spectroscopy. Vmax was significantly reduced in CFS patients (39.6 +/- 2.8 mmol/L/min, mean +/- SE) compared to controls (53.8 +/- 2.8 mmol/L/min). Two days postexercise there was no change in resting inorganic phosphate (Pi)/PCr or Vmax in the CFS patients (n = 14). In conclusion, oxidative metabolism is reduced in CFS patients compared to sedentary controls. In addition, a single bout of strenuous exercise did not cause a further reduction in oxidative metabolism, or alter resting Pi/PCr ratios.

PMID: 8618560, UI: 96189166

 

Muscle fibre characteristics and lactate responses to exercise in chronic fatigue syndrome

Russell J M Lane,a Michael C Barrett,b David Woodrow,b Jill Moss,b Robert Fletcher,b Leonard C Archardc

a Division of Neuroscience and Psychological Medicine, b Division of Diagnostic and Investigative Sciences, c Division of Biochemical Sciences, Imperial College School of Medicine, Charing Cross Hospital, London, UK

J Neurol Neurosurg Psychiatry 1998;64:362-367

OBJECTIVES---To examine the proportions of type 1 and type 2 muscle fibres and the degree of muscle fibre atrophy and hypertrophy in patients with chronic fatigue syndrome in relation to lactate responses to exercise, and to determine to what extent any abnormalities found might be due to inactivity.
METHODS---Quadriceps needle muscle biopsies were obtained from 105 patients with chronic fatigue syndrome and the proportions of type 1 and 2 fibres and fibre atrophy and hypertrophy factors were determined from histochemical preparations, using a semiautomated image analysis system.  Forty one randomly selected biopsies were also examined by electron microscopy.  Lactate responses to exercise were measured in the subanaerobic threshold exercise test (SATET).
RESULTS---Inactivity would be expected to result in a shift to type 2 fibre predominance and fibre atrophy, but type 1 predominance (23%) was more common than type 2 predominance (3%), and fibre atrophy was found in only 10.4% of cases.  Patients with increased lactate responses to exercise did have significantly fewer type 1 muscle fibres (p<0.043 males, p<0.0003 females), but there was no evidence that this group was less active than the patients with normal lactate responses.  No significant ultrastructural abnormalities were found.
CONCLUSION---Muscle histometry in patients with chronic fatigue syndrome generally did not show the changes expected as a result of inactivity.  However, patients with abnormal lactate responses to exercise had a significantly lower proportion of mitochondria rich type 1 muscle fibres.